Israel Active

Rachel, a nurse midwife attending a mother in labor at Ziv Medical Center in Safed, noticed that the baby’s head was moving in the wrong direction. She rushed them to ER, where doctors diagnosed a complete rupture of the uterus, delivered baby, and later reconstructed the mother’s womb.

Israel’s Technion Institute and the University of Toronto Artificial Intelligence Centers have partnered to develop AI solutions in the field of medicine. The first workshop took place in Ein Gedi in May.

Israel’s Sheba Medical Center has partnered UAE’s PureHealth, the largest integrated healthcare platform in the Middle East. The two will conduct joint research, promote advanced technology in healthcare, collaborate on staff training, and boost bi-lateral health tourism.

The EpiFinder device from Israel’s Omeq Medical (see previously) has just received US FDA approval. A limited US launch is planned for early 2024.

Arab Israeli Dr. Firas Mawase is head of the Neurorehabilitation and Sensorimotor Neuroscience Laboratory at Israel’s Technion. He is investigating rehabilitating the dexterity of brain-damaged patients (e.g., from a stroke), using engineering and computational tools and functional imaging of the brain.

Hebrew University of Jerusalem researchers have identified in the laboratory that the claustrum area of the brain is vital to preventing addiction to certain medications. Existing remedies could help susceptible individuals increase their resistance and self-control.

Israel’s Levana.ai is an AI-based solution that personalizes women’s prescriptions based on their cycle. It’s a platform for women who are taking long-term medication and provides doctors with recommendations regarding when and how much medication to prescribe to their patients.

Scientists at the Hebrew University of Jerusalem have converted human skin cells into functional human placenta cells. The breakthrough can help cure pregnancy-related diseases and infertility issues by generating placenta cells that won’t be rejected as foreign tissue.

Israel’s Curespec, founded by Israel’s Avner Spector, has developed Europe-approved Nephrospec. It uses an acoustic wave treatment called eHAT to treat chronic kidney disease (CKD) by promoting new blood vessel formation and restoring damaged tissue function.

The US FDA has approved a synthetic tissue substitute for the eye that will address the worldwide shortage of donors. The EverPatch from Israel’s CorNeat Vision (see previously) is made of a polymer that stimulates the cells to accept it and reinforce the sclera (outer layer of the eyeball).